SGAM
GNMK

Smith Group Asset Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Smith Group Asset Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,830
Closed -$100K – 350
2020
Q4 		$100K Hold
6,830
– – 0.01% 206
2020
Q3 		$97K Buy
+6,830
New +$104K 0.01% 200

Other funds holding GNMK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smith Group Asset Management's GNMK Position: Q1 2021 in Review

Smith Group Asset Management sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 6,830 shares — an estimated $100K sold.

Smith Group Asset Management first reported a position in GNMK in Q3 2020 and held it in 2 quarters. The position peaked at $100K in Q4 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Smith Group Asset Management reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
  • Smith Group Asset Management sold 6,830 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $100K.
  • Smith Group Asset Management first reported a position in GenMark Diagnostics, Inc in Q3 2020 and held it in 2 quarters.
  • Smith Group Asset Management's GenMark Diagnostics, Inc position peaked at $100K in Q4 2020.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Smith Group Asset Management's 13F filing for Q1 2021, filed 7 May 2021.